Literature DB >> 24748448

Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease.

Laura T Burgers1, William K Redekop, Johan L Severens.   

Abstract

OBJECTIVES: Decision analytic modelling is essential in performing cost-effectiveness analyses (CEAs) of interventions in cardiovascular disease (CVD). However, modelling inherently poses challenges that need to be dealt with since models always represent a simplification of reality. The aim of this study was to identify and explore the challenges in modelling CVD interventions.
METHODS: A document analysis was performed of 40 model-based CEAs of CVD interventions published in high-impact journals. We analysed the systematically selected papers to identify challenges per type of intervention (test, non-drug, drug, disease management programme, and public health intervention), and a questionnaire was sent to the corresponding authors to obtain a more thorough overview. Ideas for possible solutions for the challenges were based on the papers, responses, modelling guidelines, and other sources.
RESULTS: The systematic literature search identified 1,720 potentially relevant articles. Forty authors were identified after screening the most recent 294 papers. Besides the challenge of lack of data, the challenges encountered in the review suggest that it was difficult to obtain a sufficiently valid and accurate cost-effectiveness estimate, mainly due to lack of data or extrapolating from intermediate outcomes. Despite the low response rate of the questionnaire, it confirmed our results.
CONCLUSIONS: This combination of a review and a survey showed examples of CVD modelling challenges found in studies published in high-impact journals. Modelling guidelines do not provide sufficient guidance in resolving all challenges. Some of the reported challenges are specific to the type of intervention and disease, while some are independent of intervention and disease.

Entities:  

Mesh:

Year:  2014        PMID: 24748448     DOI: 10.1007/s40273-014-0155-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  59 in total

Review 1.  Modelling publication bias in meta-analysis: a review.

Authors:  A J Sutton; F Song; S M Gilbody; K R Abrams
Journal:  Stat Methods Med Res       Date:  2000-10       Impact factor: 3.021

2.  Prognostic models with competing risks: methods and application to coronary risk prediction.

Authors:  Marcel Wolbers; Michael T Koller; Jacqueline C M Witteman; Ewout W Steyerberg
Journal:  Epidemiology       Date:  2009-07       Impact factor: 4.822

3.  Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Authors:  Andrew H Briggs; Milton C Weinstein; Elisabeth A L Fenwick; Jonathan Karnon; Mark J Sculpher; A David Paltiel
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

Review 4.  The economic evaluation of medical devices: challenges ahead.

Authors:  Andreas Kirisits; W Ken Redekop
Journal:  Appl Health Econ Health Policy       Date:  2013-02       Impact factor: 2.561

5.  Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial.

Authors:  Elizabeth A Magnuson; Michael E Farkouh; Valentin Fuster; Kaijun Wang; Katherine Vilain; Haiyan Li; Jaime Appelwick; Victoria Muratov; Lynn A Sleeper; Robin Boineau; Mouin Abdallah; David J Cohen
Journal:  Circulation       Date:  2012-12-31       Impact factor: 29.690

6.  Impact of medication adherence on hospitalization risk and healthcare cost.

Authors:  Michael C Sokol; Kimberly A McGuigan; Robert R Verbrugge; Robert S Epstein
Journal:  Med Care       Date:  2005-06       Impact factor: 2.983

7.  Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

Authors:  Borislava Mihaylova; Andrew Briggs; Jane Armitage; Sarah Parish; Alastair Gray; Rory Collins
Journal:  BMJ       Date:  2006-11-10

8.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Authors:  Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins
Journal:  BMJ       Date:  2011-07-22

9.  Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--5.

Authors:  Richard Pitman; David Fisman; Gregory S Zaric; Maarten Postma; Mirjam Kretzschmar; John Edmunds; Marc Brisson
Journal:  Value Health       Date:  2012 Sep-Oct       Impact factor: 5.725

10.  Evidence synthesis for decision making 1: introduction.

Authors:  Sofia Dias; Nicky J Welton; Alex J Sutton; A E Ades
Journal:  Med Decis Making       Date:  2013-07       Impact factor: 2.583

View more
  3 in total

1.  Cost-benefit analysis of kidney transplant in patients with chronic kidney disease: a case study in Iran.

Authors:  Farzaneh Abdi; Cyrus Alinia; Ali Taghizadeh Afshari; Hasan Yusefzadeh
Journal:  Cost Eff Resour Alloc       Date:  2022-07-29

Review 2.  Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study.

Authors:  Laura T Burgers; Fleur T van de Wetering; Johan L Severens; W Ken Redekop
Journal:  BMC Health Serv Res       Date:  2016-01-20       Impact factor: 2.655

3.  A cost-effectiveness analysis of a community based CVD program in Sweden based on a retrospective register cohort.

Authors:  Lars Lindholm; Anna Stenling; Margareta Norberg; Hans Stenlund; Lars Weinehall
Journal:  BMC Public Health       Date:  2018-04-04       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.